The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Open accessAbstract
BACKGROUND: The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. METHODS: We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2. We randomly assigned 234 patients to receive standard chemotherapy alone and 235 patients to receive standard chemotherapy plus trastuzumab. Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide alone (138 women) or with trastuzumab (143 women). Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women). RESULTS: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression (median, 7.4 vs. 4.6 months; P<0.001), a higher rate of objective response (50 percent vs. 32 percent, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 months; P<0.001), a lower rate of death at 1 year (22 percent vs. 33 percent, P=0.008), longer survival (median survival, 25.1 vs. 20.3 months; P=0.01), and a 20 percent reduction in the risk of death. The most important adverse event was cardiac dysfunction of New York Heart Association class III or IV, which occurred in 27 percent of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 percent of the group given an anthracycline and cyclophosphamide alone; 13 percent of the group given paclitaxel and trastuzumab; and 1 percent of the group given paclitaxel alone. Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with standard medical management. CONCLUSIONS: Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Knowledge of these mutations has provided great insights into the molecular and biochemical abnormalities in cancer cells, and in some cases the mutated proto-oncogenes have been successfully targeted to yield therapeutic drugs for specific cancers (79, 80).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [80]
In the citing paper
“Measuring HER2 status using cfDNA offers considerable potential as a diagnostic and prognostic test (19,30,31).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [31]
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 2×
“(%) 18 (8) 8 (3) 11 (8) 6 (4) 7 (8) 2 (2)”
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816 · cited 1×
“Any type Abdominal pain 27 (3) 20 (3) 23 (2) 18 (2) 34 (3) 22 (4) Asthenia 57 (7) 56 (7) 54 (7) 55 (7) 62 (8) 57 (8) Back pain 31 (4) 22 (4) 27 (2) 16 (2) 36 (8) 30 (5) Chest pain 24 (3) 24 (4) 20 (3) 21 (2) 30 (3) 27 (5) Chills 38 (<1) 8 (<1) 35 (<1) 11 (2) 42 (1) 4 (0) Fever 53 (8) 29 (4) 56 (11) 33 (7) 47 (2) 23 (1…”
Self-citationCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765 · cited 2×
“(%) 100 (43) 66 (28) 69 (48) 52 (38) 31 (34) 14 (15)”
Self-citationRisk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814 · cited 1×
“Any type Abdominal pain 27 (3) 20 (3) 23 (2) 18 (2) 34 (3) 22 (4) Asthenia 57 (7) 56 (7) 54 (7) 55 (7) 62 (8) 57 (8) Back pain 31 (4) 22 (4) 27 (2) 16 (2) 36 (8) 30 (5) Chest pain 24 (3) 24 (4) 20 (3) 21 (2) 30 (3) 27 (5) Chills 38 (<1) 8 (<1) 35 (<1) 11 (2) 42 (1) 4 (0) Fever 53 (8) 29 (4) 56 (11) 33 (7) 47 (2) 23 (1…”
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380 · cited 1×
“analyzed (%) «1 48/143 (34) 49/136 (36) 31/91 (34) 27/95 (28) 2 38/143 (27) 48/136 (35) 32/91 (35) 35/95 (37) »3 57/143 (40) 39/136 (29) 28/91 (31) 33/95 (35)”
Self-citationGuy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193 · cited 2×
“(%) 100 (43) 66 (28) 69 (48) 52 (38) 31 (34) 14 (15)”
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072 · cited 1×
“Any type Abdominal pain 27 (3) 20 (3) 23 (2) 18 (2) 34 (3) 22 (4) Asthenia 57 (7) 56 (7) 54 (7) 55 (7) 62 (8) 57 (8) Back pain 31 (4) 22 (4) 27 (2) 16 (2) 36 (8) 30 (5) Chest pain 24 (3) 24 (4) 20 (3) 21 (2) 30 (3) 27 (5) Chills 38 (<1) 8 (<1) 35 (<1) 11 (2) 42 (1) 4 (0) Fever 53 (8) 29 (4) 56 (11) 33 (7) 47 (2) 23 (1…”
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067 · cited 1×
“analyzed (%) «1 48/143 (34) 49/136 (36) 31/91 (34) 27/95 (28) 2 38/143 (27) 48/136 (35) 32/91 (35) 35/95 (37) »3 57/143 (40) 39/136 (29) 28/91 (31) 33/95 (35)”
Self-citation
Research works printed but not linked: 9
- Press MF, 1993, Cancer Res, 53, 4960
- Chazin VR, 1992, Oncogene, 7, 1859
- Pietras RJ, 1995, Oncogene, 10, 2435
- Pietras RJ, 1994, Oncogene, 9, 1829
- Konecny G, 1999, Breast Cancer Res Treat, 57, 114
- Pietras RJ, 1999, Cancer Res, 59, 1347
- Baselga J, 1998, Cancer Res, 58, 2825
- Smith G, 1996, Semin Oncol, 23, 506
- Sledge GW, 1997, Prog Proc Am Soc Clin Oncol, 16, 1a
Cited by
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“One such is the case of breast cancer, where Her2/nu status discriminates subgroups of patients with different outcome and treatment response to trastuzumab [171].”
Background
Metadata
- Authors
- Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L.
- Affiliations
- University of California, Los Angeles (US)
- McGill University (CA)
- Genentech (US)
- University of Washington (US)
- Rotkreuzklinikum München (DE)
- Rush University Medical Center (US)
- Vall d'Hebron Hospital Universitari (ES)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-03-15
- Volume
- 344
- Issue
- 11
- Pages
- 783-792
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2318605753
- Cited by
- 11,500
- References
- 30
- Citations by year
- 2026: 245 · 2025: 292 · 2024: 386 · 2023: 423 · 2022: 405 · 2021: 396 · 2020: 428 · 2019: 434 · 2018: 466 · 2017: 493 · 2016: 538 · 2015: 566 · 2014: 586 · 2013: 605 · 2012: 563
- FWCI
- 164.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- metastatic breast cancer, HER2 overexpression, trastuzumab, monoclonal antibodies, HER2-targeted therapy, combination chemotherapy, anthracycline cardiotoxicity, doxorubicin, cyclophosphamide, paclitaxel, time to progression, survival, objective response, cardiac dysfunction, treatment efficacy and safety, HER2 amplification
- MeSH terms
- Trastuzumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Doxorubicin, Female, Heart Diseases, Humans, Middle Aged, Neoplasm Metastasis, Epirubicin, Survival Analysis, Paclitaxel, Disease Progression, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Anthracyclines, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. https://app.cochat.ai/papers/10.1056/nejm200103153441101
- The paper
- Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine. https://doi.org/10.1056/nejm200103153441101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.